Journal Options HIV
Course Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
View Collections |
|
|
|
Featured Expert Commentary
Alexandra M. Levine, MD
Chief Medical Officer
City of Hope National Medical Center
Duarte, California
Recent Articles
Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study.
Vo TT, Ledergerber B, Keiser O, et al. J Infect Dis. 2008;197:1685-1694. Capsule Summary | Expert Commentary | Abstract | Slides
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Sabin CA, Worm SW, Weber R, et al, for the D:A:D Study Group. Lancet. 2008;371:1417-1426. Capsule Summary | Expert Commentary | Abstract | Slides
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.
Patel P, Hanson DL, Sullivan PS, et al. Ann Intern Med. 2008;148:728-736. Capsule Summary | Expert Commentary | Abstract | Slides
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. J Infect Dis. 2008;197:1006-1010. Capsule Summary | Expert Commentary | Abstract | Slides
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, et al. New Engl J Med. 2008;358:2095-2106. Capsule Summary | Expert Commentary | Abstract | Slides
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA, Re VL 3rd, O'Riordan M, et al. Clin Infect Dis. 2008;46:1290-1296. Capsule Summary | Expert Commentary | Abstract | Slides
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Lundgren JD, Babiker A, El-Sadr W, et al, for the SMART Study Group. J Infect Dis. 2008;197:1145-1155. Capsule Summary | Expert Commentary | Abstract | Slides
Hepatotoxicity of Antiretroviral Drugs Is Reduced After Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients.
Labarga P, Soriano V, Vispo ME, et al. J Infect Dis. 2007;196:670-676. Capsule Summary | Expert Commentary | Abstract | Slides
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Emery S, Neuhaus JA, Phillips AN, et al, for the SMART Study Group. J Infect Dis. 2008;197:1133-1144. Capsule Summary | Expert Commentary | Abstract | Slides
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F, Lapidus N, Bedossa P, et al. Clin Infectious Dis. 2008;46:768-774. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Volume 4, Issue 4
Collection
HIV Journal Options – Volume 4, Issue 4
Program Director: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
  
- Ian Frank, MD
- Joel E. Gallant, MD, MPH
- Keith Henry, MD
|
  
- Mina Hosseinipour, MD, MPH
- Alexandra M. Levine, MD
- Michael Mugavero, MD, MHS
|
 
- Anton L. Pozniak, MD, FRCP
- David A. Wohl, MD
|
Volume 4, Issue 3
Collection
HIV Journal Options – Volume 4, Issue 3
Program Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
  
- Eric S. Daar, MD
- Joseph C. Gathe, Jr., MD, FACP, FIDSA
- Paul E. Klotman, MD
|
  
- Amanda Peppercorn, MD
- Jürgen K. Rockstroh, MD
- Paul E. Sax, MD
|
  
- Kenneth E. Sherman, MD, PhD
- Joseph K. Wong, MD
- Christina M. Wyatt, MD
|
|